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Abstract
It has become increasingly evident that a high percentage
of patients that recover from acute COVID-19 infection con-
tinue to suffer from a variety of persistent symptoms even
months after viral clearance, the most common ones be-
ing fatigue, dyspnea, anosmia, dysgeusia, cognitive dysfunc-
tion, and psychological problems, including anxiety and de-
pression. This syndrome, known as post-acute sequelae of
COVID-19 (PASC), can severely affect quality of life and rep-
resents an important health care concern. The exact causes
for the symptoms observed in patients with PASC remain to
be adequately characterized, but are likely to be associated
with multiple factors, including residual disease and/or inflam-
mation, organ damage, effects of hospitalization and/or pro-
longed ventilation, as well as effects of social isolation and
stress. This mini-review discusses evidence that may link
both inflammatory and auto-immune processes in the patho-
physiology of PASC.
Introduction
Since the beginning of the COVID-19 pandemic at the
end of 2019, great strides have been taken by the
world’s medical and scientific communities in the se-
quencing and characterization of the virus responsi-
ble, SARS-CoV-2, as well as in the pathophysiology of
the disease. While much of the focus of research has
been, understandably, on the management and treat-
ment of the acute disease, the long-term consequences
of COVID-19 infection are not well understood.[1-4]
While many people recover quickly from COVID-19, it
has become evident that many survivors of COVID-19
continue to experience a variety of symptoms weeks
and months after clearing the virus, severely affect-
ing their quality of life and placing a significant bur-
den on already compromised health care systems. This
set of symptoms in patients recovering from COVID-
19 has received different names around the world,
including post-acute sequelae of COVID-19 (PASC),
long COVID, long-haul COVID, and post-COVID Syn-
drome.[5] An evolving definition of PASC has been
suggested based on the persistence of symptoms or
development of new symptoms beyond 3 or 4 weeks
from the onset of acute COVID-19 symptoms. It can
be further divided into subacute/ongoing COVID-19—
where symptoms persist 4–12 weeks beyond acute
COVID-19—and chronic/post-COVID-19, where the
abnormalities present or persist beyond 12 weeks af-
ter acute onset of COVID-19 and are not attributable to
alternate diagnoses.[6, 7]
The symptoms suffered by PASC patients are many
and appear to involve multiple organ systems. Some
of the commonly reported symptoms are fatigue,
dyspnea, anosmia, dysgeusia, cognitive dysfunction,
and psychological problems, including anxiety and
depression.[1-3] These symptoms could be related to
residual disease and/or inflammation, organ damage,
effects of hospitalization and/or prolonged ventilation,
as well as effects of social isolation and stress.[1] Sev-
eral studies with different follow-up periods have re-
ported the incidence of persistent symptoms ranging
from about one-third in outpatients up to 90 percent in
hospitalized patients.[1-3, 8-12] These long-term seque-
lae have been reported in all age groups, and while they
appear to be more common in patients who suffered se-
vere COVID-19 or those with risk factors such as old
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age, frailty, and pre-existing clinical conditions, they
also occur in patients recovering from mild or moder-
ate disease.[3, 9, 10, 13, 14] Current research efforts are
directed at characterizing the causes and risk factors as-
sociated with PASC.
The Role of Inflammation
While the role of inflammation and autoimmunity in
COVID-19 has been demonstrated by several studies
[15, 16], their role in PASC remains poorly understood.
It has been well established that hyperinflammation
and immune dysregulation are associated with severe
outcomes in hospitalized patients with acute SARS-
CoV-2 infection and that COVID-19 is associated with
a range of non-respiratory conditions affecting multi-
ple organs, including the heart, circulatory system, kid-
neys, and liver, whose pathogenesis involves endothe-
lial activation, activation of the coagulation cascade,
and immune response against the virus .[1, 16, 17] In-
deed, several prospective studies following patients af-
ter hospital discharge have suggested that some of the
sequelae may be associated with organ damage and
persistent inflammation. For example, Raman et al.
[18] reported that serum markers of inflammation and
severity of acute illness correlated with MRI evidence
of multiorgan abnormalities and reduced exercise tol-
erance. The severity of illness during admission corre-
lated moderately with inflammatory markers (procalci-
tonin, C-reactive protein [CRP], white blood cell count,
neutrophil count, monocyte count) and signs of persis-
tent inflammation/injury in the lungs, liver, and kid-
neys, as well as decreased exercise tolerance at follow-
up assessment.
Several other studies have suggested that inflamma-
tory responses may remain present, even after viral
clearance. A study based on targeted mass spectrom-
etry found that even in asymptomatic or moderately
affected patients, there were significant remaining in-
flammatory responses 40–60 days post–viral infection
that involved anti-inflammatory response or mitochon-
drial stress proteins, suggesting that inflammatory and
biochemical pathways can remain perturbed in pa-
tients long after “recovery”.[19] Consistent with the
persistence of inflammatory responses, persistent nasal
inflammation has been reported five months after anos-
mia in COVID-19 patients.[20]
Neuropsychiatric sequelae may also have an inflam-
matory basis. The prolonged inflammatory responses
in COVID-19 may pre-dispose patients to persistent
depression and associated neurocognitive dysfunc-
tion.[21] Moreover, studies have shown that virus-
infected monocytes can propagate neuroinflammation
by releasing cytokines and promoting microglial acti-
vation.[22, 23] In addition, even in the absence of virus
in the central nervous system (CNS), peripheral cy-
tokine transmigration into the CNS may cause neu-
ropsychiatric symptoms.[24]
Finally, it is important to indicate that while inflamma-
tion seems to play an important role in the pathogen-
esis of PASC, it does not appear that PASC symptoms
are necessarily associated with the strength of anti-viral
immune responses. A study by Peluso et al. [25] in a co-
hort of individuals recovering from COVID-19 did not
find significant differences between patients with and
without PASC symptoms in long-term virus-specific T
cell or antibody responses.
The Role of Autoimmunity
Several reports have suggested that some of the PASC
may have an autoimmune origin. It has been proposed
that SARS-CoV-2 may act as a trigger for the devel-
opment of autoimmune or autoinflammatory dysreg-
ulation in genetically predisposed individuals.[26, 27]
A retrospective study from China reported a 20–50%
prevalence of autoimmune disease–related autoanti-
bodies in a group of critically ill COVID-19 patients.[28]
There are also reports of the association of several auto-
immune diseases, such as immune thrombocytopenic
purpura (ITP), Guillain-Barré syndrome (GBS), severe
thrombotic events associated with anti-phospholipid
antibodies, and Kawasaki-like inflammatory disease,
with COVID-19.[26]
A role for molecular mimicry between COVID-19 anti-
gens and self-antigens and/or bystander activation has
also been proposed as a basis for autoimmune reac-
tions arising from immune responses to shared pep-
tide sequences.[29, 30] The heterogeneity of symptoms
of PASC could have an origin in cross-reactive im-
mune responses to viral sequences. A report by Kan-
duc et al. [31] suggested that immune responses follow-
ing SARS-CoV-2 infection might lead to cross-reactions
with pulmonary surfactant and related proteins, poten-
tially contributing to SARS-CoV-2–associated lung dis-
eases. Ehrenfeld et al. [26] also reported the presence of
infiltrates of T lymphocytes, particularly CD8+ cells, in
multiple organs in deceased COVID-19 patients, con-
sistent with histological evidence of autoimmune reac-
tions in COVID-19. Additional evidence for molecu-
lar mimicry is the generation of IgG autoantibodies fol-
lowing SARS-CoV-2 infection.[32] In addition, another
study found that COVID-19 patients exhibit significant
increases in autoantibodies compared to uninfected
controls, including antibodies against immunomodula-
tory proteins, such as cytokines, chemokines, comple-
ment components, and cell surface proteins.[33]
One hypothesis attributes the development of autoim-
munity post-COVID-19 to the loss of self-tolerance as
a result of transient immunosuppression or an inade-
quate immune reconstitution in susceptible individu-
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als.[34] Whether this autoimmune process is respon-
sible for some of the PASC remains a possibility that
needs to be explored.
Conclusions
Multiple lines of evidence suggest that lingering in-
flammatory and autoimmune processes elicited as re-
sult of SARS-CoV-2 infection may be involved in the
pathogenesis of at least some of the sequelae of COVID-
19. Future research using prospective studies in pa-
tients suffering from PASC is needed to elucidate the
contributions of inflammation and autoimmunity to
their multiple symptoms and clinical presentations.
Such research would contribute to our understanding
of the pathophysiology of this syndrome and the pre-
disposing risk factors while providing clues for poten-
tial therapeutic approaches and molecular targets.
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34. Cañas CA. The triggering of post-COVID-19 autoim-
munity phenomena could be associated with both transient
immunosuppression and an inappropriate form of immune
reconstitution in susceptible individuals. Med Hypotheses
2020; 145:110345. doi: 10.1016/j.mehy.2020.110345. PMID:
33080459.
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/20 4
